• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Enfuvirtide (T-20)

Enfuvirtide (T-20)

Product ID E5220
Cas No. 159519-65-0
Purity ≥95%
Product Unit SizeCostQuantityStock
1 mg $157.50 In stock
2 mg $262.50 In stock
5 mg $472.50 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Enfuvirtide is a synthetic peptide derived from HIV-1 that exhibits antiviral activity. Enfuvirtide inhibits viral fusion, mimicking the amino acid sequence of gp41, preventing fusion of the virus to the host cell membrane. Enfuvirtide may also induce apoptosis in bystander cells.

Product Info

Cas No.

159519-65-0

Purity

≥95%

Formula

C204H301N51O64

Formula Wt.

4462.0

Synonym

T20, Fuzeon, Pentafuside, DP178.

Solubility

Best dissolved in alkaline conditions such as sterile pyrogen free 0.1% NaOH, 1% Na2CO3 or disodium phenyl phosphate at a concentration of 0.1-1 mg/mL. Insoluble in water.

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

E5220 MSDS PDF

Info Sheet

E5220 Info Sheet PDF

References

Tan JJ, Ma XT, Liu C, et al. The current status and challenges in the development of fusion inhibitors as therapeutics for HIV-1 infection. Curr Pharm Des. 2013;19(10):1810-7. PMID: 23092283.

Cai L, Gochin M, Liu K. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design. Curr Top Med Chem. 2011 Dec;11(24):2959-84. PMID: 22044229.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • E543721

    Ensartinib

    A third-generation ALK inhibitor.

    ≥98%
  • C7692

    CTX IV (6-12)

    Snake venom cardiotoxin found in Naja naja atra...

    ≥98%
  • P2100

    PF-06447475

    LRRK2 inhibitor.

    ≥98%
  • F4883

    Flutriafol

    Triazole; demethylation inhibitor, NMDA agonist...

    ≥97%
  • I0481

    Ibuprofen

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • G4581

    Glucosamine Sulfate Potassium Chloride

    Endogenous amino acid sugar involved in cartila...

    ≥98%
  • N800000

    NU-2058

    CDK1/2 inhibitor.

    ≥98%
  • M1626

    Megestrol Acetate

    Synthetic progestogen, orexigenic.

    ≥98%
  • A5133

    Amiloride Hydrochloride Dihydrate

    K+-sparing diuretic; ENaC and acid-sensing ion ...

    ≥98%
  • D1722

    Defactinib

    FAK inhibitor.

    ≥98%
  • G1869

    Geranylgeraniol

    Diterpene alcohol, geranylgeranyl pyrophosphate...

    ≥85%
  • V0269

    Vardenafil Dihydrochloride

    PDE5 inhibitor.

    ≥99%
  • H800010

    HU 308

    Cannabinoid receptor 2 selective agonist.

    ≥98%
  • T5846

    Tolfenamic Acid

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • C3263

    Ciprofloxacin Hydrochloride Monohydrate

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • V2792

    VGX-1027

    TLR4 inhibitor.

    ≥98%
  • O1177

    n-Octyl-3,4-Dimethylcaffeate

    Methylated derivative of n-octyl-caffeate.

    ≥98%
  • R0247

    Raltegravir

    HIV integrase inhibitor.

    ≥99%
  • D183740

    Desoxypipradrol

    NDRI inhibitor

    ≥98%
  • T1670

    Terazosin Hydrochloride Dihydrate

    Quinazoline; α1-adrenergic antagonist.  
    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only